(Q62030837)

English

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

clinical trial

In more languages

default for all languages

No label defined

No description defined

edit

Statements

instance of

clinical trial

0 references

title

A PHASE 2A, RANDOMIZED, DOUBLE BLIND (SPONSOR-OPEN), PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF PF-05221304 AND PF-06865571 CO-ADMINISTERED FOR 6 WEEKS IN ADULTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) (English)

0 references

medical condition

metabolic dysfunction–associated steatotic liver disease

0 references

sponsor

Pfizer

0 references

country

United States of America

0 references

start time

4 January 2019